Apigenin-4-5-7-Trihydroxyflavone-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁
Apigenin-4-5-7-Trihydroxyflavone-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁
Apigenin-4-5-7-Trihydroxyflavone-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁
Apigenin-4-5-7-Trihydroxyflavone-DataSheet-生命科學(xué)試劑-MedChemExpress_第4頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEApigeninCat. No.: HY-N1201CAS No.: 520-36-5Synonyms: 4,5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1分式: CHO分量: 270.24作靶點(diǎn): Autophagy; Cytochrome P450作通路: Autophagy; Metabolic Enzyme/Protease儲(chǔ)存式: Powder -20C 3 years4C 2 y

2、earsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 30 mg/mL (111.01 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 3.7004 mL 18.5021 mL 37.0041 mL5 mM 0.7401 mL 3.7004 mL 7.4008 mL10 mM 0.3700 mL 1.8502 mL 3.7004 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注

3、意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Apigenin種競(jìng)爭(zhēng)性 CYP2C9 抑制劑,Ki 為 2 M。IC50 & Target Ki: 2 M (CYP2C9) 1體外研究Apigenin inhibits cytochrome P450 2C9 (CYP2C9) with a Ki of 2 M in the CYP2C9 RECO system (a1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEpurified, reconstituted enzyme system containing recomb

4、inant human CYP2C9, P450 reductase, cytochromeb5, and liposomes) 1. Apigenin inhibits the cell proliferation. The growth inhibition rate (IR) of 20, 40, and 80M of Apigenin is 38%, 71%, and 99% respectively on the 7thd. after exposure to Apigenin for 24 or 48 h, theclone formation of SGC-7901 cells

5、is suppressed in a dose- and time-dependent manner. The cloningefficiency in 80 M is 9.8% and 5% after treatment with Apigenin for 24 and 48 h, while in the control group itis 40.4% and 43.4% 2.體內(nèi)研究 Apigenin (API), a natural flavonoid, possesses a broad spectrum of biological properties, includingan

6、tioxidative, anti-inflammatory, anticancer, and neuroprotective effects. Apigenin (125mg/kg and 250mg/kg) alleviates Adriamycin (ADR) (24mg/kg)-induced myocardial injury. Apigenin inhibits serum aspartateamino transferase (AST) release. Apigenin reduces serum lactate dehydrogenase (LDH) release. Api

7、geninreduces serum creatine kinase (CK) contents 3.PROTOCOLCell Assay 2 The effect of Apigenin on the viability of cells is determined by MTT assay. Near-confluent stock cultures ofhuman gastric cancer SGC-7901 cells are harvested with 0.2% EDTA and plated at a density of 2.5103/wellin 96-well micro

8、titer plates. After an overnight incubation to allow cell attachment, the medium is replaced byfresh medium containing different concentrations (0, 20, 40, and 80 M) of Apigenin. Control wells receiveDMSO (0.2%). Each concentration of Apigenin is repeated in four wells. After incubation for 24 h, on

9、e plate isassayed with a microplate reader at the wavelength of 570 nm. Before the assay, MTT (5 mg/mL in PBS) isadded to each well and incubated for 4 h, then MTT solution is removed from the wells by aspiration. Aftercareful removal of the medium, 0.1 mL of DMSO is added to each well, and the plat

10、e is shaken for 15 min.The data of 7 d are fed into the computer and the growth curve is drawn. The growth inhibition rate (IR) iscalculated 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 3Administration 3 Sixty healthy Kunming mice (262g

11、) are randomly assigned into two groups: a control group (n=15) and anADR group (n=45). The ADR group is divided into three subgroups: ADR only without Apigenin (ADR, n=15),low-dose Apigenin (125mg/kg/day, n=15), and high-dose Apigenin (250mg/kg/day, n=15). All Apigenin-treated groups are treated da

12、ily via gastric gavage for seventeen days with a 125 or 250mg/kg/day dose.ADR (3mg/kg/day) is injected intraperitoneally into animals at an interval of 48h (in total, eight times at acumulative dose of 24mg/kg). The mice in the control group receive injections of 0.9% sterile saline. On the17th day

13、after the first treatment, the mice are sacrificed, and blood samples are collected. A number ofhearts are fixed with 2.5% glutaraldehyde fixative for electron microscopy analysis, and the others are storedat -80C for western blot analysis.MCE has not independently confirmed the accuracy of these me

14、thods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) J Exp Clin Cancer Res. 2018 Oct 29;37(1):261.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE Front Pharmacol. 2018 Jun 13;9:620.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Si D, et al. Mechanism of CYP2C9 inhibition by flavon

15、es and flavonols. Drug Metab Dispos. 2009 Mar;37(3):629-34.2. Wu K, et al. Inhibitory effects of apigenin on the growth of gastric carcinoma SGC-7901 cells. World J Gastroenterol. 2005 Aug7;11(29):4461-4.3. Yu W, et al. Apigenin Attenuates Adriamycin-Induced Cardiomyocyte Apoptosis via the PI3K/AKT/mTOR Pathway. Evid BasedComplement Altern

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論